India markets close in 2 hours 12 minutes
  • BSE SENSEX

    52,384.21
    -117.77 (-0.22%)
     
  • Nifty 50

    15,720.40
    -47.15 (-0.30%)
     
  • USD/INR

    73.8130
    +0.5430 (+0.74%)
     
  • Dow

    34,033.67
    -265.63 (-0.77%)
     
  • Nasdaq

    14,039.68
    -33.22 (-0.24%)
     
  • BTC-INR

    2,900,102.75
    -70,376.00 (-2.37%)
     
  • CMC Crypto 200

    976.63
    -15.84 (-1.60%)
     
  • Hang Seng

    28,502.49
    +65.65 (+0.23%)
     
  • Nikkei

    29,018.33
    -272.68 (-0.93%)
     
  • EUR/INR

    88.1866
    -0.5969 (-0.67%)
     
  • GBP/INR

    103.1759
    -0.0926 (-0.09%)
     
  • AED/INR

    20.0510
    +0.1470 (+0.74%)
     
  • INR/JPY

    1.4959
    -0.0008 (-0.05%)
     
  • SGD/INR

    55.1350
    -0.1080 (-0.20%)
     

Global Scleroderma Epidemiology and Patient Flow Report 2021: Identify Patients Segments Through Age Groups, Gender, and Disease Sub-Types - ResearchAndMarkets.com

·2-min read

The "Global Scleroderma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Global Scleroderma Epidemiology and Patient Flow Analysis - 2021, provides Scleroderma epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.

The research provides population data to characterize Scleroderma patients, history of the disease at the population level (Scleroderma prevalence, Scleroderma incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.

Research scope:

  • Scleroderma patient flow: Scleroderma prevalence, diagnosed, and drug-treated patients

  • Countries: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries

  • Demographics: Scleroderma patients by age group, gender

  • Forecast: Scleroderma epidemiology forecast to 2035

The data from this research will help executives:

  • Establish basis for Scleroderma market sizing, assessing market potential, and developing drug forecast models

  • Identify Scleroderma patients segments through age groups, gender, and disease sub-types

  • Develop Scleroderma population-based health management frameworks

  • Evaluate Scleroderma market opportunities, identify target patient population

  • Align marketing decisions with the Scleroderma target population

  • Communicate leadership and health authorities about your Scleroderma target patient population

Key Topics Covered:

1. Research Methodology

2. Scleroderma Patients Definition

3. US Scleroderma Epidemiology and Patient Flow

4. Germany Scleroderma Epidemiology and Patient Flow

5. France Scleroderma Epidemiology and Patient Flow

6. Italy Scleroderma Epidemiology and Patient Flow

7. Spain Scleroderma Epidemiology and Patient Flow

8. UK Scleroderma Epidemiology and Patient Flow

9. Europe Scleroderma Epidemiology and Patient Flow

10. Japan Scleroderma Epidemiology and Patient Flow

11. Global Scleroderma Epidemiology and Patient Flow

For more information about this report visit https://www.researchandmarkets.com/r/6bv601

View source version on businesswire.com: https://www.businesswire.com/news/home/20210507005369/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting